Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients

被引：0
|
作者：
Dearden, H. C. [1 ]
Mason, R. [2 ]
Nguyen, B. [3 ]
Soon, J. A. [4 ]
Smith, J. L. [5 ]
Randhawa, M. [6 ]
Mant, A.
Warburton, L. [3 ]
Lo, S. [1 ]
Meniawy, T. [3 ]
Guminski, A. [1 ]
Parente, P. [7 ]
Ali, S. [6 ]
Haydon, A. [4 ]
Long, G. V. [1 ]
Carlino, M. S. [5 ]
Millward, M. [3 ]
Atkinson, V. G. [2 ]
Menzies, A. M. [1 ]
机构：
[1] Univ Sydney, Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia
[2] Princess Alexandra Hosp, Med Oncol, Woolloongabba, Qld, Australia
[3] Sir Charles Gairdner Hosp, Med Oncol, Perth, WA, Australia
[4] Alfred Hosp, Med Oncol, Melbourne, Vic, Australia
[5] Westmead Hosp, Med Oncol, Westmead, NSW, Australia
[6] Canberra Hosp, Med Oncol, Garran, Australia
[7] Box Hill Hosp Eastern Hlth, Med Oncol, Box Hill, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1256P
引用
收藏
页码：448 / 448
页数：1
相关论文
共 50 条
  • [1] Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
    Mason, Robert
    Dearden, Helen C.
    Nguyen, Bella
    Soon, Jennifer A.
    Smith, Jessica Louise
    Randhawa, Manreet
    Mant, Andrew
    Warburton, Lydai
    Lo, Serigne
    Meniawy, Tarek
    Guminski, Alexander
    Parente, Phillip
    Ali, Sayed
    Haydon, Andrew
    Long, Georgina V.
    Carlino, Matteo S.
    Millward, Michael
    Atkinson, Victoria G.
    Menzies, Alexander M.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2020, 33 (02) : 358 - 365
  • [2] Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
    Paly, Victoria Federico
    Hikichi, Yusuke
    Baker, Timothy
    Itakura, Eijun
    Chandran, Nisha
    Harrison, James
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1542 - 1552
  • [3] Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.
    Mehmi, Inderjit
    Hamid, Omid
    Hodi, F. Stephen
    Vassalo, Melinda
    Malatyali, Saundra
    Krishnarajapet, Swathi
    O'Donnell, Nan
    Castrence, Angeli
    Lim, Eunice
    Gormley, Jill
    Weber, Jeffrey S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Peter L. Quon
    Ying Xiao
    Sonja Sorensen
    Amir Abbas Tahami Monfared
    [J]. PharmacoEconomics - Open, 2019, 3 : 321 - 331
  • [5] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
    Kozak, Katarzyna
    Teterycz, Pawel
    Galus, Lukasz
    Mackiewicz, Jacek
    Galwas-Kliber, Katarzyna
    Kaminska-Winciorek, Grazyna
    Brandys, Piotr
    Cybulska-Stopa, Bozena
    Kempa-Kaminska, Natasza
    Zietek, Marcin
    Zubrowska, Justyna
    Dziura, Robert
    Dembinski, Mateusz
    Bereza, Michal
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Quon, Peter L.
    Xiao, Ying
    Sorensen, Sonja
    Monfared, Amir Abbas Tahami
    [J]. PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 321 - 331
  • [7] First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
    Kozak, K.
    Teterycz, P.
    Galus, L.
    Mackiewicz, J.
    Brandys, P.
    Cybulska-Stopa, B.
    Kempa-Kaminska, N.
    Zietek, M.
    Zubrowska, J.
    Dziura, R.
    Sobczuk, P.
    Czarnecka, A. M.
    Rutkowski, P.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S666 - S666
  • [8] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN
    Baker, T. M.
    Paly, V. F.
    Thybo, S.
    Hultberg, M.
    Minacori, R.
    Kotapati, S.
    Sabater, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A730 - A731
  • [9] Metastatic Melanoma Nivolumab plus Ipilimumab is the better First-line Therapy
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8) : 448 - 449
  • [10] ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Quon, P.
    Xiao, Y.
    Sorensen, S.
    Schultz, M.
    Monfared, Tahami A. A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A441 - A442
12345